Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

Hiroshi Hirose, Toshihide Kawai, Yukihiro Yamamoto, Matsuo Taniyama, Motowo Tomita, Koichi Matsubara, Yasunori Okazaki, Tatsuya Ishii, Yuko Oguma, Izumi Takei, Takao Saruta

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P < .01 for all), and HbA1c (6.7 ± 0.8 to 6.1% ± 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P < .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.

Original languageEnglish
Pages (from-to)314-317
Number of pages4
JournalMetabolism: Clinical and Experimental
Volume51
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

pioglitazone
Body Fat Distribution
Adiponectin
Type 2 Diabetes Mellitus
Subcutaneous Fat
Intra-Abdominal Fat
Serum
Body Mass Index
Blood Pressure
Fasting
Insulin
Umbilicus
Glucose
Glycosylated Hemoglobin A
Therapeutics
LDL Cholesterol
HDL Cholesterol
Triglycerides
Hormones

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. / Hirose, Hiroshi; Kawai, Toshihide; Yamamoto, Yukihiro; Taniyama, Matsuo; Tomita, Motowo; Matsubara, Koichi; Okazaki, Yasunori; Ishii, Tatsuya; Oguma, Yuko; Takei, Izumi; Saruta, Takao.

In: Metabolism: Clinical and Experimental, Vol. 51, No. 3, 2002, p. 314-317.

Research output: Contribution to journalArticle

Hirose, Hiroshi ; Kawai, Toshihide ; Yamamoto, Yukihiro ; Taniyama, Matsuo ; Tomita, Motowo ; Matsubara, Koichi ; Okazaki, Yasunori ; Ishii, Tatsuya ; Oguma, Yuko ; Takei, Izumi ; Saruta, Takao. / Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. In: Metabolism: Clinical and Experimental. 2002 ; Vol. 51, No. 3. pp. 314-317.
@article{94273fe9513d43bb88fe2a0fcf64add6,
title = "Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes",
abstract = "The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P < .01 for all), and HbA1c (6.7 ± 0.8 to 6.1{\%} ± 0.6{\%}, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P < .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.",
author = "Hiroshi Hirose and Toshihide Kawai and Yukihiro Yamamoto and Matsuo Taniyama and Motowo Tomita and Koichi Matsubara and Yasunori Okazaki and Tatsuya Ishii and Yuko Oguma and Izumi Takei and Takao Saruta",
year = "2002",
doi = "10.1053/meta.2002.30506",
language = "English",
volume = "51",
pages = "314--317",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

AU - Hirose, Hiroshi

AU - Kawai, Toshihide

AU - Yamamoto, Yukihiro

AU - Taniyama, Matsuo

AU - Tomita, Motowo

AU - Matsubara, Koichi

AU - Okazaki, Yasunori

AU - Ishii, Tatsuya

AU - Oguma, Yuko

AU - Takei, Izumi

AU - Saruta, Takao

PY - 2002

Y1 - 2002

N2 - The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P < .01 for all), and HbA1c (6.7 ± 0.8 to 6.1% ± 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P < .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.

AB - The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P < .01 for all), and HbA1c (6.7 ± 0.8 to 6.1% ± 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P < .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.

UR - http://www.scopus.com/inward/record.url?scp=0036125944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036125944&partnerID=8YFLogxK

U2 - 10.1053/meta.2002.30506

DO - 10.1053/meta.2002.30506

M3 - Article

VL - 51

SP - 314

EP - 317

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 3

ER -